Continuing Concerns Over Imported Pharmaceuticals: Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, First Session, June 7, 2001, Volume 4
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
U.S. Government Printing Office, 2001 - Drug adulteration - 191 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
50 dosage units addictive agencies Americans APIs border bulk BURR ceutical Chairman committee companies Congress consumers controlled sub Controlled Substance Act controlled substances counterfeit drugs counterfeit pharmaceuticals counterfeit products criminal dangerous declared DEGETTE deKieffer DEUTSCH diazepam DINGELL diversion drug abuse Drug Enforcement Administration drug products enforcement entering the U.S. FDA approved FDA's Federal flunitrazepam Food and Drug foreign GREENWOOD hearing HUBBARD illegal importation of controlled inspectors international mail Internet pharmacies investigations issue labels Laredo legitimate look mail facilities manufactured Mexican Mexico NAGEL Novartis Nuevo Laredo Oxycodone Oxycontin packages parcels patients percent personal importation phar pharma pharmaceutical products pharmacist pills PREPARED STATEMENT prescription drugs problem public health purchased question regulation regulatory reimportation require risk RODE Rohypnol safety scription SHEPHERD shipments STEARNS STUPAK Subcommittee tablets testimony Texas tion TRUNDLEY U.S. citizens U.S. Customs Service U.S. residents unapproved